Background-Although the benefits of drug-eluting stents (DES) for reducing restenosis after percutaneous coronary intervention are well established, the impact of alternative rates of DES use on population-level outcomes is unknown.
S ince their introduction into US clinical practice in 2003, drug-eluting stents (DES) have dramatically altered the practice of interventional cardiology. Numerous randomized trials and observational studies have demonstrated significant reductions in clinical and angiographic restenosis compared with bare metal stents (BMS), [1] [2] [3] [4] [5] leading to widespread use of DES in both approved and "off-label" applications. 5, 6 Nonetheless, several critical questions regarding DES remain unresolved. In particular, little is known about the optimal rate of DES use from either a clinical or economic perspective, specifically, whether DES should be used for virtually all patients or whether more selective use would be preferred.
Clinical Perspective on p 1037
Although several studies have examined the impact of DES use on the outcomes of patients undergoing percutaneous coronary intervention (PCI) at the population level, to date, these studies have either directly compared patients receiving DES versus BMS 4, 7 or indirectly compared patient cohorts treated before and after the introduction of DES into clinical practice. 8, 9 These studies thus provide insight into the overall benefits of DES technology but do not specifically address the issue of their efficient application. Recently, several health technology assessments have concluded that DES should be reserved for select patient subsets such as patients with diabetes mellitus or those with long lesions or small vessels. 10, 11 However, these findings were based largely on a combination of expert opinion and decision-analytic models without external validation. 12, 13 In January 2007, the US Food and Drug Administration responded to emerging safety concerns regarding DES with an advisory statement that cautioned against their use in patients with unapproved or untested indications. 14 As a result, the practice of DES use shifted within a few months from nearuniversal DES use to a more selective approach. 15, 16 These recent changes in US practice patterns provide a unique opportunity to study the impact of alternative rates of DES use using empirical data. Accordingly, we used data from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry, a multicenter study of the practice and outcomes of PCI in the United States, to examine the clinical and economic impact of these practice changes on a population level. The goal of these analyses was to understand the clinical value and costeffectiveness of near-universal DES use versus more selective use by comparing 1-year outcomes and cardiovascular-specific costs after PCI across these 2 distinct time periods.
Methods
The methods and population of the EVENT registry have been described previously. 6, 17 Briefly, EVENT is a collaborative effort to assess the contemporary practice and outcomes of PCI in the Data on patient characteristics, clinical presentation, and treatment were collected prospectively on standardized case report forms and submitted to the data coordinating center. Patients were contacted by telephone at 6 and 12 months after the index PCI, and information on subsequent hospitalizations and medication use was obtained. Events noted at follow-up included death, myocardial infarction (MI), repeat revascularization, and stent thrombosis. All follow-up events were reviewed by experienced clinical cardiologists (J.M.S., J.B.L., D.J.C.), and all repeat revascularization procedures were adjudicated by reviewing case report forms or by contacting the enrolling center for additional medical records when necessary. The study protocol was approved by ethical review committees at all participating institutions; all patients provided written informed consent.
The clinical end points of interest for this analysis were the occurrence of target lesion revascularization (TLR) after discharge (defined as repeat PCI or bypass graft placement for a stenosis occurring in or within 5 mm of the stents placed during index PCI), 1 target vessel revascularization (TVR), any repeat revascularization, death, and MI.
Cost Analysis
Costs were assessed for each patient from the perspective of the healthcare system (modified societal perspective). 18 Because costs were not measured directly as part of the EVENT registry, we estimated initial treatment costs for each patient by adding the cost of stents implanted to the mean Medicare reimbursement for balloon angioplasty. 19 Each stent was assigned a cost of $2287 per DES or $850 per BMS on the basis of average hospital acquisition costs in 2007. 20 Additional costs ($8986 per event) 21 were incorporated to account for urgent repeat PCI during the initial hospitalization, which differed slightly between the time periods. Follow-up costs were estimated for repeat revascularization procedures and their associated hospitalizations from mean Medicare reimbursement rates for the appropriate diagnosisrelated group or the weighted average of potential diagnosis-related group when Ͼ1 was possible. Finally, costs for dual antiplatelet therapy were estimated by assuming a cost of $4/d 22 for the observed duration of use in the registry. Because there were no significant differences in the rates of other cardiovascular events (eg, death or MI) or in the use of other cardiovascular medications, all other costs were assumed to be equal between the time periods of our analysis. All costs are reported in 2007 US dollars; discounting was not performed because the maximum follow-up was 1 year.
Statistical Methods
Because the goal of this study was to examine the impact of alternative rates of DES use, we divided the population into 2 groups: patients enrolled in waves 1, 2, and 3 (2004 to 2006, liberal DES era) and patients enrolled in wave 4 (2007, selective DES era). Baseline patient, angiographic, and treatment-related characteristics were compared between these 2 treatment eras by use of the Student t test for continuous variables (including cost data) and the 2 test for categorical variables. To identify factors associated with DES use in the selective era, we used hierarchical logistic regression that accounted for clustering at the patient level. In these models, an unstructured covariance matrix was used to model repeated observations within patients.
Event rates between hospital discharge and 1-year follow-up were estimated with the Kaplan-Meier method and compared by use of the log rank statistic. We used hierarchical Cox regression models (frailty models) that assumed a gamma distribution for the random site effect to estimate the unadjusted and adjusted risks of these events in 2007 compared with 2004 to 2006. 23 These models adjusted for a broad range of sociodemographic, clinical, angiographic, and treatment-related factors that were associated with each outcome in univariate analyses (see the online-only Data Supplement for a complete list of covariates). We further adjusted for differences in patient and treatment characteristics between the 2 cohorts by including a propensity score for the probability of a patient undergoing PCI in waves 1 through 3 versus wave 4; variables included in the propensity score are listed in the online-only Data Supplement.
Formal cost-effectiveness analysis was performed to compare the difference in mean 1-year costs (including index hospitalization, follow-up antiplatelet therapy, and repeat revascularization events) with the incremental health benefit achieved during the liberal versus selective DES eras. For these analyses, health benefits were defined as the differences in clinical events (TLR, TVR, or any repeat revascularization) and quality-adjusted life-years (QALYs) between the 2 time periods. For the QALY measure, quality-adjusted life expectancy was calculated from published estimates for patients with and without repeat revascularization procedures. 24 Bootstrap methods (1000 replicates) were used to examine the joint distribution of cost and effectiveness differences between the 2 time periods across regions of the cost-effectiveness plane. 25 Finally, we used net benefit regression analysis to generate risk-adjusted cost-effectiveness acceptability curves for each outcome. 26 As described above, to adjust for differences in patient and treatment characteristics between the 2 cohorts, we included the propensity score for the probability of a patient undergoing PCI in waves 1 through 3 versus wave 4 in each net benefit regression model.
Statistical analyses were performed with SAS software (version 9.2, SAS Institute, Cary, NC) and R statistical software version 2.9.2. A value of PՅ0.05 was considered statistically significant unless otherwise specified.
Results
Between August 2004 and December 2007, 10 144 patients were enrolled in the EVENT registry. Over this time period, the proportion of patients receiving at least 1 DES decreased from 92% in 2004 to 2006 (liberal DES era; nϭ7587) to 68% in 2007 (selective DES era; nϭ2557; PϽ0.001; Figure 1 ). Table 1 shows the baseline clinical characteristics of patients in the 2 treatment periods. In general, most characteristics were similar between the liberal and selective DES periods. However, compared with the 2004 to 2006 era, patients treated in 2007 were more likely to have undergone PCI in the setting of an acute coronary syndrome. Angiographic char- acteristics were also generally stable over time with no significant differences in the extent of coronary artery disease or the number of vessels and lesions attempted during the index procedure (Table 2 ). However, on average, patients treated in 2007 received slightly fewer stents and slightly shorter total stent lengths than those treated in 2004 to 2006.
Patient and Procedural Characteristics
Correlates of DES versus BMS use in the 2007 cohort are displayed in Table 3 . During this time period, DES use was more likely among younger patients and in those undergoing PCI for stable coronary artery disease, left main or left anterior descending artery lesions, bifurcations, in-stent restenosis, longer lesions, and smaller vessels. Use of DES was less frequent among patients who were receiving warfarin at the time of index PCI.
Procedural and In-Hospital Outcomes
There were no significant differences in overall angiographic success or procedural complications between the 2 cohorts (Table 4 ). Although the need for urgent PCI during the index hospitalization was slightly higher in 2007 compared with 2004 to 2006, there were no differences in other complications, including death, stent thrombosis, urgent coronary artery bypass graft surgery, or composite bleeding, between the 2 time points. 
Clinical Outcomes
Of the 10 144 patients enrolled at baseline, 22 patients died during the index hospitalization, and 300 (3%) were missing follow-up information. Figure 2 shows the cumulative rates of postdischarge events over 1 year in the liberal and selective DES use eras. Compared with the 2004 to 2006 period, patients treated in 2007 were more likely to require TLR during follow-up (5.1% versus 4.1%; Pϭ0.03), with similar results in risk-adjusted analyses (adjusted hazard ratio for 2007 versus 2004 to 2006, 1.36; 95% confidence interval [CI], 1.04 to 1.78; Table 5 ). Similar trends were observed in outcomes of TVR (6.5% versus 5.6%; Pϭ0.09; adjusted hazard ratio, 1.23; 95% CI, 0.97 to 1.55) and any repeat revascularization (10.6% versus 10.1%; Pϭ0.42; adjusted hazard ratio, 1.05; 95% CI, 0.88 to 1.27). No significant differences were observed in the incidence of death or the composite of death or MI between the 2 periods in either unadjusted or risk-adjusted analyses.
When we considered the total number of repeat revascularization procedures (ie, the sum of all repeat procedures that each patient underwent over 1 year) in both groups, the mean differences in TLR and TVR procedures increased to 1.9 additional TLR events per 100 patients treated (95% CI, 0.8 to 2.9) and 1.6 more TVR events per 100 patients treated (95% CI, 0.3 to 2.9) in 2007 versus 2004 to 2006. PCI indicates percutaneous coronary intervention; LAD, left anterior descending artery.
*Reference category for all variables is the absence of characteristic unless otherwise specified.
†From hierarchical logistic regression models that accounted for clustering at the patient level. †Information on discharge use of thienopyridine therapy was not collected in wave 1 and therefore was estimated from patients' reported use during follow-up.
Economic Outcomes and Cost-Effectiveness
Cardiovascular-specific costs for the initial hospitalization and 12-month follow-up period are summarized in Table 6 . On average, initial hospital costs were $659 per patient higher during 2004 to 2006 compared with 2007 (95% CI for difference, 561 to 758; PϽ0.001), driven largely by the more frequent use of DES and greater numbers of stents implanted per patient during the earlier time period. Although costs related to repeat revascularization were somewhat lower during the 2004 to 2006 time period, these cost savings were insufficient to fully offset the higher initial treatments costs. Thus, total 1-year cardiovascular costs per patient were $401 Figure 3 , and the corresponding cost-effectiveness acceptability curves based on net benefit regression are shown in Figure 4 . As shown in Figure 4A , the risk-adjusted, disease-specific incremental cost-effectiveness ratio (ICER) for the liberal versus selective DES use eras was $16 000 per TLR event avoided, and the probability that the ICER was Ͻ$10 000 per TLR event avoided was 30%. Results were somewhat less favorable for TVR (ICERϭ$20 000 per TVR avoided; Figure 4B ) and any repeat revascularization (ICERϭ$27 000 per repeat revascularization avoided; Figure 4C ). In the generic analysis, the ICER for the liberal versus selective DES use eras was $433 000 per QALY gained, and the probability that the ICER was Ͻ$50 000 per QALY gained was 9% ( Figure 4D ).
Sensitivity analyses demonstrated that the ICER for the liberal versus selective DES eras would be Ͻ$10 000 per repeat revascularization avoided if the cost differential be-tween DES and BMS were Ͻ$800 per stent, whereas an ICER Ͻ$50 000 per QALY gained would require a cost difference of Ͻ$600 per stent.
Discussion
Although the benefits of DES on reducing restenosis and the need for repeat revascularization after PCI are well established, 5, 27 little is known about the effect of alternative rates of DES use on clinical and economic outcomes of PCI at the population level. Furthermore, although randomized trials have demonstrated consistent benefits of DES across a variety of patient and lesion characteristics in terms of relative risk reductions, 1,2 both risk-benefit and cost-effectiveness considerations are determined by absolute risk reductions, which may vary with patient characteristics. In this study, we used data from EVENT, a multicenter observational study of the practice and outcomes of PCI in the United States, to examine temporal changes in DES use associated with emerging concerns regarding DES safety and the impact of these alternative use patterns on clinical and economic outcomes.
Consistent with other studies, 15, 16 we found that between 2004 to 2006 and 2007, there was a reduction of Ϸ25% in DES use (from 92% to 68%) among unselected patients undergoing PCI. This reduction was accompanied by a small but statistically significant increase in clinical restenosis (ie, TLR), which persisted after controlling for broad range of clinical, angiographic, and treatment-related factors. There were no differences, however, in other end points, including death or MI. In parallel with these changes in practice and outcomes, the estimated cost of cardiovascular care (including dual antiplatelet therapy and repeat revascularization procedures) decreased by Ϸ$400 per patient between the liberal and selective DES eras. Formal cost-effectiveness analysis thus demonstrated that the ICER for liberal versus selective DES use was Ϸ$20 000 per TLR or TVR event avoided. When more patient-centered outcomes such as any repeat revascularization and qualityadjusted life expectancy were considered, however, the ICERs increased to Ϸ$30 000 per repeat revascularization avoided and Ϸ$400 000 per QALY gained. Within the US healthcare system, ICERs of Ͻ$10 000 per repeat revascularization avoided 24 and Ͻ$50 000 to $100 000 per QALY gained have generally been considered economically attractive. 28, 29 These findings thus suggest that in an era of constrained resources, a more selective approach to DES use would be preferred, at least on economic grounds. With nearly 1 million PCI procedures annually in the United States, 30 adoption of the more selective DES strategy would be expected to result in Ϸ$400 million/y in annual cost savings to the US healthcare system.
Comparison With Previous Studies
Several previous studies have examined the impact of the introduction of DES on clinical outcomes of PCI at the population level. Malenka and colleagues 8 examined 2-year rates of death, MI, and repeat revascularization among Medicare patients undergoing nonemergent coronary stenting between October 2002 (100% BMS) and December 2003 (62% DES). They found that compared with the BMS-only era, patients undergoing PCI in the DES era had significantly lower rates of repeat PCI or coronary artery bypass graft surgery with similar rates of death or MI. Hannan and colleagues 9 reported similar findings in an analysis of patients undergoing de novo PCI from 2002 to 2004 in the New York State Registry. More recently, Ryan and colleagues 31 extended these findings by examining clinical and economic outcomes among Medicare patients undergoing any coronary revascularization procedure (either PCI or coronary artery bypass graft surgery) before and after the advent of DES. They found that, at the population level, the introduction of DES was associated with a 24% increase in the use of PCI as an initial revascularization strategy (compared with bypass surgery) and net cost savings of $1680 per revascularized patient at the 2-year follow-up.
Although these previous studies have demonstrated the clinical and economic benefits of DES technology on overall PCI outcomes, no study to date has compared the outcomes of alternative rates of DES use. By using a time-based natural experiment to directly compare the outcomes of nearly universal DES utilization (in 2004 to 2006) with those of a more selective approach (in 2007), our study thus provides a more nuanced assessment of the benefits and costs of DES versus BMS than was previously available.
Clinical and Policy Implications
Although we found that more selective use of DES was associated with important economic benefits and little reduction in clinical effectiveness compared with near-uniform use, it is difficult to draw specific conclusions regarding the optimal patient population for DES or BMS use from our study. Examination of the treatment patterns in our 2007 cohort demonstrated that DES were used preferentially in patients who were younger or treated for stable coronary artery disease, as well as in longer lesions and smaller vessels. Although these findings suggest that operators were selecting patients for DES implantation who would be expected to experience higher rates of restenosis with BMS (and presumably greater benefits from DES), there was considerable heterogeneity in patient selection across the 2 time periods. Nonetheless, it does appear that interventional cardiologists were able to integrate a variety of clinical and angiographic factors so as to select patients for DES who were expected to experience higher rates of restenosis with BMS and thus most likely to derive clinical benefit from their antirestenotic properties.
Study Limitations
Our findings should be interpreted in the context of the following limitations. First, our analysis cannot directly identify the "optimal" cohort of patients who may experience maximal benefit with DES because no attempt was made to specify a particular algorithm for DES selection during the 2 time periods. Consequently, one cannot easily extrapolate our results into a specific treatment paradigm for the individual clinician. Nonetheless, we believe that our finding that, compared with a more selective approach to DES use, a near-universal approach provides little incremental benefit at a substantial cost to the healthcare system has considerable relevance in the current healthcare environment.
Second, the time horizon for our cost-effectiveness analysis was limited to 1 year. However, the principal benefit of DES versus BMS is a reduction in restenosis, a process that is largely complete within 12 months of the index procedure. 32 As a result, previous studies have demonstrated that the absolute magnitude of benefit for revascularization-related events is stable between 1 and 5 years after initial PCI. 33, 34 Our approach therefore captures the time period of maximal effect to provide meaningful estimates of both event rates and costs and thus is consistent with most of the original economic analyses of DES. 35, 36 Third, because our study was a temporal comparison, it is possible that some of the differences in outcomes that we observed were a function of secular changes in patients or practice patterns beyond stent selection. However, the time frame encompassed by our study was relatively brief, with few differences in baseline clinical or angiographic characteristics between the time periods.
Fourth, the validity of our temporal comparison depends on the representativeness of our patient population. Although the need to obtain informed consent before PCI for all patients in the EVENT registry precluded enrollment of all PCI patients, considerable effort was undertaken to ensure consistent enrollment of a high proportion of eligible patents. 17 As a result, Ͼ70% of all PCI patients were enrolled at the participating centers, and the proportion was similar across the 4 waves and the 55 enrolling sites. The similarity between the profile of our patients and that reported in previous publications of PCI practice in the United States across these same time periods provides further evidence of the representativeness of our study cohort. 16, 37 Fifth, our analysis of quality-adjusted life expectancy was based on utility weights derived from an external population (rather than direct measurement from the EVENT cohort). It is reassuring that our conclusions were similar when we used "disease-specific" cost-effectiveness ratios because they were derived directly from our study population. Finally, by using empirical time-based data, we were limited to a comparison of 2 different DES use patterns. Thus, although our analysis suggests that 92% DES use is economically unattractive by conventional standards, it is uncertain whether 68% use is truly optimal from a cost-effectiveness perspective. In particular, whether an even more restrictive approach to DES use policy would result in an unacceptable loss of clinical benefits or even higher long-term costs remains unknown.
Conclusions
In this large representative cross section of US PCI practice, a substantial reduction in DES use, concurrent with emerging safety concerns, was associated with a small but statistically significant increase in TLR and a modest reduction in total cardiovascular costs. There were no differences in any other clinical end points. These findings suggest that although clinical outcomes may be marginally better, an overall strategy of unrestricted use of DES may not represent an efficient use of scarce healthcare resources.
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